Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in high-risk localized extremity soft tissue sarcoma
NCT03092323Phase 2Active, not recruiting
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Jul 2017
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in soft tissue sarcoma (STS), sponsored by Sarcoma Alliance for Research through Collaboration. Primary endpoint: Disease-Free Survival at 2 years. Started Jul 2017; status: active, not recruiting.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03092323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092323.